YARD-FORCE
31.1.2024 02:51:31 CET | Business Wire | Press release
Yard Force takes a bold step forward with the introduction of the REVOLA robot lawn mower, challenging the norm in the Outdoor Power Equipment (OPE) market, with fully-featured and Virtual Boundary Technology. Recent data from Statista reveals that the OPE market reached a staggering $33.56 billion in 2022, with an anticipated Compound Annual Growth Rate (CAGR) of 5.6% from 2022 to 2027, projecting a market size of $44.07 billion. Lawn mowers, especially those integrating lithium-ion technology, are at the forefront of this growth, boasting an estimated CAGR of 9%, outpacing other OPE categories.
The REVOLA robot lawn mower from Yard Force emerges as a game-changer, not just as an efficient grass-cutting tool but as a solution to longstanding challenges in the industry. Packed with advanced technologies, the REVOLA promises users a unique and efficient lawn-mowing experience.
Key Features of the REVOLA Robot Lawn Mower:
1. Virtual Boundary Navigation System: The Virtual Boundary Navigation System in the REVOLA is called APNT (Advanced Positioning and Navigation Technology) leverages a multi-faceted approach to ensure accurate and reliable navigation. It utilizes satellite positioning for global location awareness, path planning algorithms for efficient route optimization, ultrasonic sensor for proximity sensing, and VSLAM (Visual Simultaneous Localization and Mapping) technology for real-time visual mapping and positioning. The VSLAM technology is a standout feature, allowing the REVOLA to create a dynamic map of its surroundings, navigate with precision, and adapt to changes in the environment. This technology plays a crucial role in overcoming obstacles, providing flexibility, and ensuring a robust navigation experience even in challenging conditions.
2. Addressing Existing Pain Points: The REVOLA addresses common challenges faced by traditional virtual boundary robot mowers. Unlike its counterparts, the REVOLA's VSLAM technology enables it to accurately cutting even though satellite signal is weak. Additionally, positioning inaccuracies caused by obstacles such as trees, houses, or electric poles are mitigated through the advanced VSLAM technology. This results in a seamless and trouble-free mowing experience for users, eliminating the frustrations associated with traditional navigation limitations.
3. Enhanced Safety Features: Safety is a top priority for the REVOLA, as validated by TÜV Rheinland tests. Traditional satellite-based mowers may face challenges with larger stones, potentially causing damage to blades or posing risks to objects like water pipes and toys. The REVOLA mitigates these risks through its intelligent obstacle recognition and detection system by integrated ultrasonic sensor and RGB camera. This system ensures that the mower can identify obstacles, including stones larger than 10 cm, and take appropriate actions to navigate around them, promoting a safe mowing process and protecting both the mower and the surrounding environment.
4. Optimized Battery Consumption Performance: The REVOLA is designed for efficient and long-lasting performance with its optimized battery consumption thanks to the systematic cut algorithm. Equipped with a powerful 28V 5.7Ah battery, the high-efficiency brushless motor further enhances efficiency, operating at optimal speeds of revolutions per minute (RPM) to ensure precise grass cutting. This combination of a high-capacity battery and a high- efficiency brushless motor contributes to the REVOLA's effectiveness in maintaining lawns while maximizing battery life.
5. Smart Connectivity: Smart Connectivity is a key aspect of the REVOLA, providing users with remote control and monitoring capabilities. The mower is equipped with Bluetooth, 4G, and Wi-Fi connectivity, ensuring comprehensive network coverage. Users can leverage the dedicated app to monitor the mower's progress from anywhere, allowing for real-time tracking of mowing activities. This connectivity not only enhances user convenience but also allows for more personalized and efficient lawn care based on specific preferences and needs.
6. RGB Recognition: RGB recognition in the REVOLA involves the use of Red, Green, and Blue color channels to identify and differentiate various elements within the lawn. The mower employs a sophisticated camera that captures images of the lawn. By analyzing the color spectrum and structure of the grass, the REVOLA can distinguish between different types of vegetation, ensuring a more targeted and efficient mowing process. This feature allows the mower to adapt its mowing pattern based on the specific characteristics of the lawn, resulting in a more precise and customized cutting experience.
7. OTA (Over the Air) Updates: The OTA update capability of the REVOLA enables the mower to receive software updates and enhancements remotely, without requiring manual intervention. This feature ensures that the REVOLA remains current with the latest technological developments, performance optimizations, and bug fixes. Manufacturers can regularly release updates to improve the mower's functionality, address any identified issues, or introduce new features. Users can conveniently download and install these updates over the air, ensuring that their REVOLA mower continues to operate at its best without the need for physical updates or visits to a service center.
Future Outlook and Industry Impact:
As the OPE market continues to evolve, the REVOLA robot lawn mower positions itself as a revolutionary product. Its advanced VSLAM technology, coupled with a user-friendly design, addresses longstanding industry challenges and paves the way for the future of intelligent lawn management. Yard Force's commitment to innovation and excellence sets the REVOLA apart, making it a frontrunner in reshaping the landscape of outdoor power equipment.
About Yard Force:
Yard Force is a world recognized brand dedicated to providing innovative outdoor power equipment solutions. With a focus on cutting-edge technology and user-friendly designs, Yard Force aims to transform the lawn care experience for users worldwide.
Follow Yard Force:
- Website: https://www.yardforce.eu
- Facebook: https://www.facebook.com/YardForceEurope
*Note: The information provided in this press release is based on data available as of Jan 23rd, 2024. Any future developments or changes may not be reflected in this release. *
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130520868/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom